UltraSight

Name: UltraSight
Brand: UltraSight

UltraSight is an AI-assisted cardiac workflow solution that provides real-time mobile application guidance for transthoracic echocardiography acquisition, structured training, interpretation workflow integration, and analytics to support non-sonographer clinical providers under qualified physician oversight.

Est 2018|11 Ref Customers

LinkedIn 3K|Website|FTEs 39

01Competitive Landscape

| Aspect | UltraSight | Caption Health (Caption Guidance) | AISAP (POCUS OS / POCAD) | |--------|------------|-----------------------------------|---------------------------| | Starting Price | Not publicly listed (quote-based) | Not publicly listed (enterprise quote-based) | Not publicly listed (enterprise quote-based; offers software credit program messaging) | | Appropriate for | Health systems aiming to expand FoCUS acquisition capacity beyond sonographers, with physician oversight and workflow integration | Similar objective: AI-guided acquisition for non-experts; historically positioned around guided echo acquisition | Teams seeking AI-assisted cardiac measurements/interpretation and structured reporting/middleware across devices | | Key Strength | FDA-cleared AI guidance for acquiring standard adult TTE views; vendor describes the program as a combined training, guidance, workflow, and stewardship system | Early regulatory pathway recognition (De Novo regulatory recognition) and established presence in AI-guided acquisition category | Device-agnostic positioning with emphasis on diagnostic algorithms, reporting, and middleware | | Key Weakness | Limited public third-party reviews; limited public documentation of enterprise security/compliance artifacts; compatibility constraints may increase TCO | Pricing and implementation details are not public; may require integration with specific hardware/workflows | Pricing and clearance scope require verification; integration effort may be non-trivial | - Direct competitors and their key differentiators - Caption Health - Caption Guidance has a De Novo regulatory listing and is a recognized predicate device in the category. - UltraSight’s 510(k) summary references Caption Guidance as a predicate. - AISAP - Positions itself as an FDA-cleared operating system for POCUS devices, emphasizing diagnostic modules, reporting, and broad device support. - Butterfly Network - Provides a handheld ultrasound ecosystem with published probe and membership pricing for individual users; organization plans typically require vendor engagement. - Feature comparison: where UltraSight may have advantages or disadvantages (evidence-based) - Potential advantages - A regulatory-cleared intended use focused on assisting non-expert users with acquisition of standard adult cardiac views. - Vendor messaging combines training, acquisition guidance, interpretation workflow, and stewardship into an integrated program. - Potential disadvantages - Compatibility constraints with specific ultrasound systems could limit fleet-agnostic deployment compared with platform-agnostic competitors. - Other vendors may publish clearer pricing or offer broader modality coverage (beyond cardiac echo), depending on the competitor. - Pricing comparison: value proposition vs alternatives - UltraSight: pricing is quote-based and not publicly posted. - Hardware-inclusive alternatives (illustrative only) - Butterfly publishes consumer and membership pricing for probes and individual users; organization pricing is typically by inquiry. - EchoNous indicates configuration-based pricing and markets certain bundles with indicative pricing, but exact subscription and bundle costs require vendor quotes. - Implication - UltraSight is typically procured as a clinical software and workflow program rather than a consumer hardware purchase, and procurement often involves multi-stakeholder enterprise negotiations. - Market share and adoption trends - Publicly available market-share figures specific to UltraSight were not identified. Industry reports and analyst lists include UltraSight among ultrasound AI participants but do not constitute evidence of adoption scale.

01Competitive Landscape

Aspect	UltraSight	Caption Health (Caption Guidance)	AISAP (POCUS OS / POCAD)
Starting Price	Not publicly listed (quote-based)	Not publicly listed (enterprise quote-based)	Not publicly listed (enterprise quote-based; offers software credit program messaging)
Appropriate for	Health systems aiming to expand FoCUS acquisition capacity beyond sonographers, with physician oversight and workflow integration	Similar objective: AI-guided acquisition for non-experts; historically positioned around guided echo acquisition	Teams seeking AI-assisted cardiac measurements/interpretation and structured reporting/middleware across devices
Key Strength	FDA-cleared AI guidance for acquiring standard adult TTE views; vendor describes the program as a combined training, guidance, workflow, and stewardship system	Early regulatory pathway recognition (De Novo regulatory recognition) and established presence in AI-guided acquisition category	Device-agnostic positioning with emphasis on diagnostic algorithms, reporting, and middleware
Key Weakness	Limited public third-party reviews; limited public documentation of enterprise security/compliance artifacts; compatibility constraints may increase TCO	Pricing and implementation details are not public; may require integration with specific hardware/workflows	Pricing and clearance scope require verification; integration effort may be non-trivial

Direct competitors and their key differentiators
- Caption Health
  - Caption Guidance has a De Novo regulatory listing and is a recognized predicate device in the category.
  - UltraSight’s 510(k) summary references Caption Guidance as a predicate.
- AISAP
  - Positions itself as an FDA-cleared operating system for POCUS devices, emphasizing diagnostic modules, reporting, and broad device support.
- Butterfly Network
  - Provides a handheld ultrasound ecosystem with published probe and membership pricing for individual users; organization plans typically require vendor engagement.
Feature comparison: where UltraSight may have advantages or disadvantages (evidence-based)
- Potential advantages
  - A regulatory-cleared intended use focused on assisting non-expert users with acquisition of standard adult cardiac views.
  - Vendor messaging combines training, acquisition guidance, interpretation workflow, and stewardship into an integrated program.
- Potential disadvantages
  - Compatibility constraints with specific ultrasound systems could limit fleet-agnostic deployment compared with platform-agnostic competitors.
  - Other vendors may publish clearer pricing or offer broader modality coverage (beyond cardiac echo), depending on the competitor.
Pricing comparison: value proposition vs alternatives
- UltraSight: pricing is quote-based and not publicly posted.
- Hardware-inclusive alternatives (illustrative only)
  - Butterfly publishes consumer and membership pricing for probes and individual users; organization pricing is typically by inquiry.
  - EchoNous indicates configuration-based pricing and markets certain bundles with indicative pricing, but exact subscription and bundle costs require vendor quotes.
- Implication
  - UltraSight is typically procured as a clinical software and workflow program rather than a consumer hardware purchase, and procurement often involves multi-stakeholder enterprise negotiations.
Market share and adoption trends
- Publicly available market-share figures specific to UltraSight were not identified. Industry reports and analyst lists include UltraSight among ultrasound AI participants but do not constitute evidence of adoption scale.

Aspect

UltraSight

Caption Health (Caption Guidance)

AISAP (POCUS OS / POCAD)

Starting Price

Not publicly listed (quote-based)

Not publicly listed (enterprise quote-based)

Not publicly listed (enterprise quote-based; offers software credit program messaging)

Appropriate for

Health systems aiming to expand FoCUS acquisition capacity beyond sonographers, with physician oversight and workflow integration

Similar objective: AI-guided acquisition for non-experts; historically positioned around guided echo acquisition

Teams seeking AI-assisted cardiac measurements/interpretation and structured reporting/middleware across devices

Key Strength

FDA-cleared AI guidance for acquiring standard adult TTE views; vendor describes the program as a combined training, guidance, workflow, and stewardship system

Early regulatory pathway recognition (De Novo regulatory recognition) and established presence in AI-guided acquisition category

Device-agnostic positioning with emphasis on diagnostic algorithms, reporting, and middleware

Key Weakness

Limited public third-party reviews; limited public documentation of enterprise security/compliance artifacts; compatibility constraints may increase TCO

Pricing and implementation details are not public; may require integration with specific hardware/workflows

Pricing and clearance scope require verification; integration effort may be non-trivial

UltraSight

01Competitive Landscape

02Market Map

01Competitive Landscape

02Market Map